BioCryst Expects NIAID To Stop COVID Indication For Galidesivir

Free stock photo of analysis, biochemistry, biology


Image Source: Unsplash

BioCryst Pharmaceuticals (BCRX) announced that it expects the National Institute of Allergy and Infectious Diseases to discontinue the pursuit of a COVID-19 indication for galidesivir.

"Based on the company's ongoing discussions with the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, a major funding partner for the program, BioCryst expects NIAID to continue their support for the development of galidesivir with a focus on biodefense threats, such as Marburg virus disease, and to discontinue the pursuit of a COVID-19 indication for galidesivir," the company said in a statement.

BioCryst revealed data from part 1 of a clinical trial of galidesivir, saying it showed that galidesivir was safe and generally well tolerated in patients infected with SARS-CoV-2, the virus that causes COVID-19. The trial was not designed or sized to demonstrate clinical efficacy and no clinical efficacy benefit with galidesivir treatment compared to placebo treatment was observed in the trial. Shares of BioCryst are down 6% to $7.80 in premarket trading.


 

Disclaimer: TheFly's news is intended for informational purposes only and does not claim to be actionable for investment decisions. Read more at  more

How did you like this article? Let us know so we can better customize your reading experience. Users' ratings are only visible to themselves.

Comments

Leave a comment to automatically be entered into our contest to win a free Echo Show.